{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"363"}],"units":"Participants"}],"description":"Myeloma Response Definitions - Using International Uniform Response Criteria:\n\nProgressive Disease (PD)\n\nFor patients not in CR or sCR, progressive disease requires one or more of the following:\n\n* \\>25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 0.5 g/dL.\n* \\>25% increase in 24-hour urine protein electrophoresis, which must also be an absolute increase of at least 200 mg/24 hours.\n* Absolute increase in the difference between involved and uninvolved FLC levels (absolute increase must be \\>10 mg/dl), only in patients without measurable paraprotein in the serum and urine.\n* \\>25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%.\n* Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.","groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"OG000","title":"Chemotherapy and Transplant Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants With Disease Progression","type":"SECONDARY","unitOfMeasure":"Participants"}